A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Alpha-1 Antitrypsin (AAT) (Glassia(®)) in the Treatment of Recent-Onset Type 1 Diabetes

Our aim was to assess the efficacy, safety, and tolerability of alpha-1 antitrypsin (AAT) as a therapeutic modality for β-cell preservation in patients with recent-onset type 1 diabetes. Seventy type 1 diabetes patients (37 males; mean age 13.1 ± 4.1years) were randomized to treatment with 22 infusi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebenthal, Yael, Brener, Avivit, Hershkovitz, Eli, Shehadeh, Naim, Shalitin, Shlomit, Lewis, Eli C., Elias, Dana, Haim, Alon, Barash, Galia, Loewenthal, Neta, Zuckerman-Levin, Nehama, Stein, Michal, Tov, Naveh, Rachmiel, Marianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928874/
https://www.ncbi.nlm.nih.gov/pubmed/31795482
http://dx.doi.org/10.3390/ijms20236032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928874/
https://www.ncbi.nlm.nih.gov/pubmed/31795482
http://dx.doi.org/10.3390/ijms20236032

Ejemplares similares